Advisory Services

Experts from Greenleafs Drug, Medical Device, and Compliance Teams provide investors with extensive research and due diligence on potential deals that require regulatory risk analyses before and after decisions and transactions.

The firm’s multidisciplinary team uses its deep regulatory expertise to perform risk assessments that take into account business objectives, transaction timelines, and the industry landscape. Greenleaf’s comprehensive due diligence services evaluate a company’s pipeline, or a specific asset, in the following areas:

  • Product development and review
  • Quality manufacturing
  • Identification of regulatory risk

The result is an unbiased analysis identifying a target company’s key regulatory risks, likelihood of the risks materializing, potential impact on the business, and opportunities to manage and mitigate risks in order to achieve desired regulatory outcomes.

Learn more about Greenleaf’s Advisory Services:

Download Advisory Services Capabilities Deck

Download Advisory Services Info Sheet


Greenleaf’s advisory services include research and analysis of the following potential data sources:


  • Product development
  • Regulatory pathway evaluation
  • Assessment of FDA submissions
  • Compliance status
  • Quality manufacturing
  • Preclinical and clinical quality systems
  • Compliance with reporting requirements
  • Distribution and supply chain
  • Adverse event reporting
  • Marketing and promotion

Advisory Team Members